Imprimis Pharmaceuticals, Inc. (NASDAQ:IMMY) is at $1.64 having a low of $1.60 and high of $1.73. This range of trading distinguishes the stock as one of the day’s most volatile.
Shares are trading at $1.64 well below $1.99, the 50 day moving average and quite a bit lower than the 200 day moving average of $3.03. The 50 day moving average went down by -17.47% and the 200 day average went down $-1.39 or -45.82%.
Imprimis Pharmaceuticals, Inc. news headlines.
Short traders are more bullish on Imprimis Pharmaceuticals, Inc. recently if you take a look at the motion in short interest. The firm recorded a fall in short interest between August 15, 2017 and August 31, 2017 of -0.96%. Short shares decreased 8,058 over that period. With short interest at 832,885 and short average daily volume at 221,294, the short-interest ratio is 4.0 and the percentage of shorted shares is 0.04% as of August 31.
Imprimis Pharmaceuticals, Inc. (Imprimis), launched on January 11, 2006, is involved in the development, production and dispensing of compounded pharmaceuticals. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. The Company, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases. The Company is also developing Custom Compounding Choice business, which is focused on developing and dispensing a portfolio of non-proprietary compounded drugs for humans and animals in therapeutic areas that may be overlooked by commercial pharmaceutical companies. The Company also offers customizable compounding products that consist of sterile injectable and non-sterile integrative medicine therapies that are used in various therapeutic areas, including oncology, autoimmunity, chronic infectious diseases and endocrine and metabolic diseases..